Table 1 Patients’ baseline characteristics
From: Nasal high-flow bronchodilator nebulization: a randomized cross-over study
Variable | N = 25 |
|---|---|
Female/male | 10 (40%)/15 (60%) |
Age (years) | 60 (53; 68) |
Main respiratory disease | |
Asthma | 9 (36%) |
COPD | 14 (56%) |
Other | 2 (8%) |
Height (cm) | 169 (165; 176) |
Weight (kg) | 75 (64; 80) |
Body mass index (high/weight2) | 26 (23; 29) |
FEV1 (L) | 1.83 (1,38; 2,03) |
Percentage of predicted (%) | 60 (53; 71) |
FEV1/vital capacity (%) | 54 (45; 60) |
Functional residual capacity (L) | 5,0 (3,9; 6,0) |
Percentage of predicted (%) | 150 (139; 171) |
Residual volume (L) | 4,0 (2,9; 4,4) |
Percentage of predicted (%) | 172 (154; 184) |
Presence of expiratory flow limitation | 6 (24%) |